Tissue-factor fusion proteins induce occlusion of tumor vessels

Thrombosis Research

Volumn 125, Issue , 2010, Pages S143-S150

  Schwöppe, Christian ^a   Kessler, Torsten ^a   Persigehl, Thorsten ^a   Liersch, Ruediger ^a   Hintelmann, Heike ^a   Dreischalück, Johannes ^a   Ring, Janine ^a   Bremer, Christoph ^a   Heindel, Walter ^a   Mesters, Rolf M ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cancer; Truncated tissue factor; Tumor targeting; Tumor homing peptides; Vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; HYBRID PROTEIN; OLIGOPEPTIDE; THROMBOPLASTIN;

ANIMAL; ARTICLE; BLOOD VESSEL; DRUG EFFECT; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; MALE; MOUSE; NEOPLASM; NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS; OLIGOPEPTIDES; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN;

EID: 77955493301     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70033-5     Document Type: Article

References (49)

1. Folkman, J, Watson, K, Ingber, D, Hanahan, D, Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:6219 (1998), 58–61.
2. Folkman, J, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995), 27–31.
3. Carmeliet, P, Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000), 389–395.
4. Hanahan, D, Folkman, J, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996), 353–364.
5. Robert, S, Kerbel. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?. Science, 12, 2006, 1171.
6. Ferrara, N, Alitalo, K, Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5 (1999), 1359–1364.
7. O'Farrell, AM, Foran, JM, Fiedler, W, Serve, H, Paquette, RL, Cooper, MA, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003), 5465–5476.
8. Murphy, DA, Makonnen, S, Lassoued, W, Feldman, MD, Carter, C, Lee, WM, Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43–9006). Am J Pathol 169:5 (2006), 1875–1885.
9. Thorpe, PE, Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:2 (2004), 415–427.
10. Arap, W, Pasqualini, R, Ruoslahti, E, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:5349 (1998), 377–380.
11. Morrissey, JH, Macik, BG, Neuenschwander, PF, Comp, PC, Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:3 (1993), 734–744.
12. Nilsson, F, Kosmehl, H, Zardi, L, Neri, D, Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:2 (2001), 711–716.
13. Liu, C, Huang, H, Donate, F, Dickinson, C, Santucci, R, El-Sheikh, A, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62:19 (2002), 5470–5475.
14. Ran, S, Gao, B, Duffy, S, Watkins, L, Rote, N, Thorpe, PE, Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58:20 (1998), 4646–4653.
15. Huang, X, Molema, G, King, S, Watkins, L, Edgington, TS, Thorpe, PE, Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:5299 (1997), 547–550.
16. Hu, P, Yan, J, Sharifi, J, Bai, T, Khawli, LA, Epstein, AL, Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 63:16 (2003), 5046–5053.
17. Brooks, PC, Clark, RA, Cheresh, DA, Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:5158 (1994), 569–571.
18. Burg, MA, Pasqualini, R, Arap, W, Ruoslahti, E, Stallcup, WB, NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59:12 (1999), 2869–2874.
19. Carnemolla, B, Balza, E, Siri, A, Zardi, L, Nicotra, MR, Bigotti, A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108:3 (1989), 1139–1148.
20. Curnis, F, Arrigoni, G, Sacchi, A, Fischetti, L, Arap, W, Pasqualini, R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:3 (2002), 867–874.
21. Dvorak, HF, Brown, LF, Detmar, M, Dvorak, AM, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:5 (1995), 1029–1039.
22. Felding-Habermann, B, Mueller, BM, Romerdahl, CA, Cheresh, DA, Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 89:6 (1992), 2018–2022.
23. Kessler, T, Pfeifer, A, Silletti, S, Mesters, RM, Berdel, WE, Verma, I, et al. Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies. Ann Hematol 81:Suppl 2 (2002), 69–70.
24. Kessler, T, Fehrmann, F, Bieker, R, Berdel, WE, Mesters, RM, Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Current drug targets 8:2 (2007), 257–268.
25. Pasqualini, R, Koivunen, E, Kain, R, Lahdenranta, J, Sakamoto, M, Stryhn, A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:3 (2000), 722–727.
26. Pfeifer, A, Kessler, T, Silletti, S, Cheresh, DA, Verma, IM, Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 97:22 (2000), 12227–12232.
27. Rettig, WJ, Garin-Chesa, P, Healey, JH, Su, SL, Jaffe, EA, Old, LJ, Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89:22 (1992), 10832–10836.
28. Ellerby, HM, Arap, W, Ellerby, LM, Kain, R, Andrusiak, R, Rio, GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:9 (1999), 1032–1038.
29. Hood, JD, Bednarski, M, Frausto, R, Guccione, S, Reisfeld, RA, Xiang, R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296:5577 (2002), 2404–2407.
30. Ruoslahti, E, Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:6 (2000), 435–442.
31. Curnis, F, Arrigoni, G, Sacchi, A, Fischetti, L, Arap, W, Pasqualini, R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62 (2002), 867–874.
32. Kessler, T, Bieker, R, Padro, T, Schwöppe, C, Persigehl, T, Bremer, C, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 11:17 (2005), 6317–6324.
33. Kessler, T, Schwöppe, C, Liersch, R, Schliemann, C, Hintelmann, H, Bieker, R, et al. Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol 5 (2008), 1–8.
34. Bieker, R, Kessler, T, Schwöppe, C, Padró, T, Persigehl, T, Bremer, C, et al. Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience. Blood 113:20 (2009), 5019–5027.
35. Koivunen, E, Gay, DA, Ruoslahti, E, Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 268:27 (1993), 20205–20210.
36. Ruf, W, Rehemtulla, A, Morrissey, JH, Edgington, TS, Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 266:4 (1991), 2158–2166.
37. Hanes, CS, Studies on plant amylases: The effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley. Biochem J 26:5 (1932), 1406–1421.
38. Corti, A, Curnis, F, Arap, W, Pasqualini, R, The neovasculature homing motif NGR: more than meets the eye. Blood 112 (2008), 2628–2635.
39. Curnis, F, Sacchi, A, Gasparri, A, Longhi, R, Bachi, A, Doglioni, C, et al. Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res 68:17 (2008), 7073–7082.
40. Curnis, F, Longhi, R, Crippa, L, Cattaneo, A, Dondossola, E, Bachi, A, et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 281:47 (2006), 36466–36476.
41. Persigehl, T, Bieker, R, Matuszewski, L, Wall, A, Kessler, T, Kooijmann, H, et al. Antiangiogenic tumor treatment: Early non-invasive monitoring with USPIO-enhanced MR Imaging in mice. Radiol 244:2 (2007), 449–456.
42. Persigehl, T, Matuszewski, L, Kessler, T, Wall, A, Meier, N, Ebert, W, et al. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Invest. Radiol 42:12 (2007), 781–796.
43. Teicher, BA, Flipping the wound that doesn't heal: the upside of coagulation in cancer. Blood 113:20 (2009), 4827–4828.
44. Banner, DW, D'Arcy, A, Chene, C, Winkler, FK, Guha, A, Konigsberg, WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380:6569 (1996), 41–46.
45. Stone, MJ, Ruf, W, Miles, DJ, Edgington, TS, Wright, PE, Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. The Biochemical journal 310:Pt 2 (1995), 605–614.
46. Ntziachristos, V, Bremer, C, Tung, C, Weissleder, R, Imaging cathepsin B up-regulation in HT-1080 tumor models using fluorescence-mediated molecular tomography (FMT). Acad Radiol Aug 9:Suppl 2 (2002), 323–325.
47. Ntziachristos, V, Bremer, C, Graves, EE, Ripoll, J, Weissleder, R, In vivo tomographic imaging of near-infrared fluorescent probes. Mol Imaging 1:2 (2002), 82–88.
48. Von Wallbrunn, A, Höltke, C, Zühlsdorf, M, Heindel, W, Schäfers, M, Bremer, C, In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging 34:5 (2007), 745–755.
49. Von Wallbrunn, A, Waldeck, J, Höltke, C, Zühlsdorf, M, Mesters, RM, Heindel, W, et al. In vivo optical imaging of CD13/APN-expression in tumor xenografts. J Biomed Opt, 13(1), 2008, 011007.